Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Heart Failure October 13, 2025
Specialist Care Can Improve HF Outcomes Across the Board October 13, 2025
A recent study out of the U.K. suggests that multidisciplinary team management could significantly reduce death or rehospitalization risk for HF patients across the LVEF spectrum. Based in a single U.K. county, the Buckinghamshire analysis examined 2.1k patients hospitalized for acute heart failure who received either specialist care or standard care over a 618-day follow-up […]
Cardiology Testing October 9, 2025
Screening For Lp(a) is Still Too Uncommon October 9, 2025
A recent JACC analysis of the Epic Cosmos database suggests lipoprotein(a) screening is still one of cardiology’s most neglected risk assessment tools, representing a serious gap in the way we evaluate patients’ CVD risk. To learn more about Lp(a) testing trends, researchers searched for Lp(a) screening patterns in the Epic Cosmos database from 2015-2024 across […]
Cardiogenetics October 6, 2025
Secondary Cardiomyopathy Isn’t so Secondary After All October 6, 2025
Secondary cardiomyopathies might not be caused by environmental factors after all, after a massive four-biobank study found that their development is a lot more dependent on which combination of genetic risks you already have. The multi-biobank genetic analysis examined nearly 1.3M individuals identifying 3.4k people with secondary cardiomyopathies (70 PPCM, 2,281 ACM, 1,063 CCM). Upon […]
Heart Failure October 2, 2025
Where HF is Headed – Takeaways from HFSA 2025 October 2, 2025
Cardiac Wire attended its first ever Heart Failure Society of America meeting this year, exploring everything from the latest pharmaceutical advancements to the complex relationship between cardio-renal health and beyond. Here are some of the big takeaways from HFSA 2025. Heart Failure Comes in Many Forms: While the gold-standard for diagnosing heart failure is still […]
More Stories
Cardiology September 29, 2025
CVD: A Bigger Global Health Problem Than We Realize September 29, 2025
The latest Global Burden of Disease study revealed that cardiovascular disease is a bigger part of the global health battle than previously thought, underscoring the impact of CVD on population-level health despite medical advances. Presented at the UN General Assembly 2025, the Global Burden of Disease study looked at cardiovascular disease patterns across regions and […]
Cardiovascular Disease Solutions September 26, 2025
Breaking Barriers in Coronary Care: Abbott’s New IVL System Targets Severe Calcification September 26, 2025
By: Jennifer Jones-McMeans, PhD , Divisional Vice President of Global Clinical Affairs at AbbottSponsored by Abbott Severe calcification is one of the complex challenges faced by interventional cardiologists. Intravascular Lithotripsy (IVL) is emerging as a promising treatment option for Coronary Artery Disease (CAD). Traditional therapies for calcified arterial blockages include cutting balloons and atherectomy. However, […]
Cholesterol Reduction September 25, 2025
Meds-to-Beds Improve PCSK9 Inhibitor Access and Efficacy September 25, 2025
PCSK9 inhibitors might finally reach their clinical potential in the patients who need them most, after the ELL-ASCVD study demonstrated that a Meds-to-Beds program delivering these medications before hospital discharge significantly improved patient uptake. The ELL-ASCVD program enrolled 72 patients immediately following their revascularization procedures, with 69% post-PCI, 18% post-CABG, and 13% post-peripheral interventions, finding […]
Cardiovascular Disease September 22, 2025
OCTOPUS: What Really Causes MI in Younger Patients September 22, 2025
Young heart attack patients might actually be a completely different disease population than previously understood, after the OCTOPUS registry analysis revealed that the causes of early MI and the people who get them aren’t what’s expected. The OCTOPUS registry analyzed 4k cardiac events between 2003-2018, using medical record linkage to classify MI etiologies in patients […]
Cardiology Practices September 18, 2025
What Cardiologists Say vs. What Patients Hear September 18, 2025
Cardiovascular risk communication might be failing patients when they need it most, after the HARIPA study revealed significant disconnects between patient and physician perceptions of future cardiovascular risk and procedural complications. The HARIPA study surveyed cardiology inpatients and their physicians from October 2022 to March 2023, using structured questionnaires to assess risk perception and communication […]
Digital Health September 15, 2025
TRICORDER Shows Potential of AI Stethoscopes September 15, 2025
Results from the massive TRICORDER study suggest Eko Health’s AI-powered stethoscopes could change the way primary care providers perform cardiac screening, potentially catching thousands more patients for cardiologists to treat. The TRICORDER study results encompassed 205 NHS GP practices over 12 months, with nearly 1,000 providers performing more than 12.8k AI-stethoscope exams in routine care […]
Cardiology September 11, 2025
Cardiac Wire’s ASE 2025 Takeaways September 11, 2025
The American Society of Echocardiography left an echo this year in Music City as it celebrated its 50th year. Among the studies and products unveiled at ASE 2025, here are Cardiac Wire’s top five takeaways from the meeting. Premium Echo Has Found its Stride – Although most typically think of ultrasound as a lower cost […]
Cardiology Business September 8, 2025
Edwards Acquires Vectorious, Bolsters HF Portfolio September 8, 2025
Edwards Lifesciences took another step towards becoming a major player in remote heart failure monitoring, after fully acquiring Israeli startup Vectorious Medical Technologies for $497M in cash. Vectorious’ monitoring device is known as the V-LAP system and it uses a minimally invasive approach to achieve continuous HF monitoring through a tiny, battery-free sensor implanted in […]
Cardiology Pharmaceuticals September 4, 2025
The Differences in HCM, Results from ODYSSEY and MAPLE September 4, 2025
In a big step towards better hypertrophic cardiomyopathy treatments, two separate studies presented at ESC suggest cardiac myosin inhibitors’ efficacy depends critically on whether patients have the obstructive or nonobstructive form of the disease. Two different trials presented insightful outcomes at ESC 2025, with MAPLE-HCM testing aficamten versus metoprolol in obstructive HCM patients, and ODYSSEY-HCM […]
Cardiology August 28, 2025
Cardiologists, Practice What You Preach! August 28, 2025
Cardiologists might be struggling with the same lifestyle challenges they counsel patients about, as a national survey of ACC members revealed significant gaps between what physicians’ recommend and how they act. The ACC CardioSurve study surveyed 166 U.S. cardiologists about their training in lifestyle medicine and clinical recommendations across all six lifestyle pillars, revealing some […]
Obesity Care August 25, 2025
GLP-1s Work, But Not for Free August 25, 2025
Real-world semaglutide (Wegovy) patients might be experiencing a healthcare cost paradox, after a recent analysis in JAMA showed that GLP-1s successfully reduce weight and improve cardiovascular risk factors, but lead to increased patient healthcare expenditures in the short term. The real-world analysis examined 23.5k adults prescribed semaglutide between January 2018 and January 2025 across two […]
Electrophysiology August 21, 2025
Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025
Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]
Cardiology Pharmaceuticals August 18, 2025
Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025
New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]
Surgeries & Interventions August 14, 2025
TEER Could Save Lives in AFMR Patients August 14, 2025
Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]
Cardiology Business August 11, 2025
The State of the TAVR Market in 2025 August 11, 2025
2025 has been a year of many cardiology trends, with one stand out technology capturing much of the spotlight – transcatheter aortic valves. To keep our valves in a row, Cardiac Wire has compiled a breakdown of the top TAVR makers, movers, shakers, and potential future players. Starting off with the biggest player, Edwards Lifesciences […]
Cardiology Pharmaceuticals August 7, 2025
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes August 7, 2025
The largest and longest tirzepatide study to date just confirmed that Eli Lilly’s Mounjaro has surpassed its older GLP-1, Trulicity, in practically every way, with significant gains when it comes to cardiovascular benefits. The SURPASS-CVOT study represents the most comprehensive incretin analysis to date, comparing MACE rates in 13k T2D patients with ASCVD on either […]
Cardiovascular Disease August 4, 2025
The Impact of Physical Activity Before and After CV Events August 4, 2025
A long-term analysis of the CARDIA study revealed that moderate-to-vigorous physical activity steadily declines from young adulthood through midlife, but patients destined to develop cardiovascular disease experience rapid activity decreases more than a decade before their first event. Collecting data over 37 years, researchers tracked ~3k participants from young adulthood to middle age and paired […]
Cardiology Pharmaceuticals July 31, 2025
AstraZeneca’s Anselamimab Comes Up Short in Phase 3 Trial July 31, 2025
In a setback to one of its rarer disease pipelines, AstraZeneca’s amyloidosis antibody, anselamimab, failed to significantly reduce all-cause mortality and CV hospitalizations in the CARES Phase 3 trial’s overall patient population. The CARES clinical program was the largest prospective cardiac AL amyloidosis investigation to date, enrolling 406 patients to test whether anselamimab could reduce […]